Single, dual and pan-PPAR agonists are under development for the pharmacological treatment of NASH, we bring you the latest videos on this.
Prof Gracia-Sancho, Spain, discusses his oral presentation at the Liver meeting 2019 in Boston and the reasons why PPAR agonists could be a very valuable therapeutic option for the treatment of advanced chronic liver disease.
Prof Michael Roden, Germany discusses the reasons why patients with NASH have an increased cardiovascular risk and the potential for PPAR agonists to improve outcomes. This video was filmed in Boston during the Liver meeting 2019.
Prof Gyongyi Szabo, USA discusses the role of PPARs in NASH fibrogenesis. This video was filmed in Boston during the Liver meeting 2019.
Prof Frank Tacke, Germany, discusses the role of PPARs in adipose tissue and liver inflammation. This video was filmed in Boston during the Liver meeting 2019.
Prof. Sven Francque, Chair of the PanNASH initiative reviews the current management options in NASH and the many molecules in development. It sheds light on the rationale for PPAR agonists as a promising and very valuable therapeutic option with systemic potential, for what happens in the liver and outside of the liver.